ABSTRACT. Background and Objectives. Anecdotal reports on the efficacy of secretin in autism raised great hopes for the treatment of children with this disorder. Initial single-dose, randomized, controlled trials failed to demonstrate any therapeutic effects of secretin. The present study is the first to test the outcome of repeated doses and to examine whether there is a subgroup of children who are more likely to achieve positive effects.
A utism is a severe, life-long neurobiological disorder with high morbidity. The disorder affects virtually all areas of functioning, notably social, communicative, cognitive, and behavioral. Prevalence is estimated to be as high as 5/1000 for the full spectrum of autistic disorders 1 and prognosis is generally poor. 2, 3 To date, the cause of autism remains unknown, and there is no specific medical treatment. Psychopharmacological management continues to be far from satisfactory, with no pharmacologic agent having been shown to alter the natural history of the disorder.
Against this background, recent clinical reports of a positive response to secretin in children with autism have generated widespread interest in and demand for this hormone. In 1998, Horvath et al 4 reported an uncontrolled case series of 3 autistic children who showed marked improvements in their social and language skills after administration of secretin for an investigative gastrointestinal (GI) procedure. This report received considerable media attention and escalating claims of a potential cure for autism resulted in likely thousands of children with autism being given secretin injections.
Recently published placebo-controlled trials [5] [6] [7] failed to show any effect of secretin on cognitive, language, or behavioral measures, suggesting that secretin is not an effective treatment in autism. It remains possible, however, that these studies may have missed clinically significant changes because of the use of a single injection 5, 7 (vs multiple doses), the use of human synthetic 5 rather than porcine secretin, small sample sizes, 6, 7 the use of measures that may not be sensitive to drug effects, 6 and the failure to consider possible subgroups of responders, notably those with GI symptomatology. To address these possibilities, the current study investigated the effect of 2 doses of porcine secretin in 64 children 2 to 7 years of age with autism. The primary question was whether secretin results in reliable improvements in autistic symptomatology, language, and/or cognitive functioning compared with a placebo. We also addressed the issue of possible subgroups of responders as well as possible adverse effects of multiple doses.
METHODS

Participants
Sixty-eight children (ages 2-7 years) were recruited through the Child Development Center of the Hospital for Sick Children (HSC); 64 completed the study. All children met criteria for autism or autism spectrum disorder according to the Autism Diagnostic Interview-Revised (ADI-R) 8, 9 and the Autism Diagnostic Observation Scale-Generic (ADOS-G) 10 ; in addition, all had previously received a diagnosis of autism or pervasive developmental disor-der from clinicians in the community based on criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. 11 All parents gave written informed consent for their child's participation in the study. Approval for this project was obtained from the research ethics board at HSC.
Procedure
Children were randomly assigned to secretin or placebo groups using a random numbers table. A block, randomized design was used to ensure equal numbers of children ages 2 to 4 years and 5 to 7 years in each group. Participants, parents, and examiners were all blind to group membership. Before administration of the drug or placebo, participants were assessed on all medical, clinical, and psychological measures (described below). Diagnoses were confirmed using the ADI-R 8,9 together with the ADOS-G. 10 The ADI-R is an investigator-directed parent interview that elicits the necessary information to make a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition 11 diagnosis of autism. It has been validated for use in children Ͼ18 months old and yields a total score for autistic symptoms, as well as subscores for social and communicative impairments and repetitive behaviors. Interrater agreement on the ADI-R is excellent (0.94 -0.97). 9 The ADOS-G was used both to confirm the diagnosis and as an outcome measure during follow-up visits. ADOS-G sessions were videotaped to assess interrater reliability (reliability ϭ 83.8% on 5% of all ADOS-G assessments). Follow-up assessments were conducted 3 weeks after each injection based on the expectation from previous reports 4 that an effect would be most apparent at that time. These assessments included all clinical measures, except the ADI-R and cognitive testing. Cognitive measures were repeated only at the final follow-up visit. The ADI-R and ADOS-G were administered by W. R. and J. B., who have reliability with the University of Chicago, and then by B. M. and L. W., who have reliability with W. R. and J. B.
Drug Administration
Participants were admitted to the HSC day treatment unit on 2 occasions, 6 weeks apart. Children fasted for 3 hours before intravenous injections of porcine secretin or placebo. Injections were administered by a physician not participating in assessments or data analysis. To minimize the likelihood of parents guessing group membership (ie, possible unblinding), the following script was recited to all parents before injection. "This infusion may cause an immediate allergic reaction. Therefore, we will first give a test dose to monitor for the reaction. If no reaction occurs after 1 minute, it is safe to give the full dose. The injection may also cause some temporary skin redness or flushing which may persist for a short time afterward."
Participants first received a test dose of 0.1 mL of secretin or saline placebo. After vital signs were taken, 2 mL/kg (0.2 mL/kg) of secretin or saline was injected. The children were monitored for 4 hours after the injection. Heart rate, respiratory rate, blood pressure, temperature, and transcutaneous oxygen saturation levels were monitored. Nutritional/fluid intake and output was measured periodically. A urine sample was checked for specific gravity between 2 and 4 hours postinjection. A physician examined each patient before discharge.
Clinical and Psychological Measures
Measures were selected based on their sensitivity to autistic symptomatology and to developmental levels of the children under study.
Autistic Symptomatology
The ADOS-G 10 was used to measure language, social, and behavioral features of autism at baseline and at both follow-up assessments. This scale involves direct observation of a child in a semistructured play sequence that elicits information about social relatedness (eg, eye contact, joint attention), play skills, verbal and gestural communication, and repetitive behaviors. The ADOS-G consists of modules appropriate for differing levels of developmental and language abilities.
Cognitive Functioning
The Leiter International Performance Scale-Revised 12,13 (Brief IQ) was used to measure nonverbal intellectual ability at baseline and final follow-up. This measure is standardized for ages 3 to 8 years and is used widely in the field. It has excellent test-retest reliability (0.96), and Leiter scores are highly correlated with scores of the Wechsler Intelligence Scale for Children-III (0.85-0.86). For those children unable to complete IQ testing during the study (6 secretin and 5 placebo), existing clinical data (ie, Vineland Adaptive Behavior Scales 14 ) were used to determine level of functioning.
Language
The Preschool Language Scale, III (PLS-3), 15 which has been validated for use with children ages 2 weeks through 6 years 11 months, was used to provide measures of Expressive, Receptive, and Total Language functioning at baseline and both follow-up assessments. Good internal consistency of Total Language Scores is reported for the entire age range (0.74 -0.94). Subscale internal consistency ranges from 0.75 to 0.91 for children older than 1 year 6 months. Test-retest reliability (assessed for ages 3 years to 5 years 11 months) is excellent (range: 0.82-0.94), as is interrater reliability (0.89 for ages 3 years 3 months to 6 years 11 months).
Visual-Spatial Attention
Performance on a simple visual orienting task has been shown to reliably distinguish children with autism from other developmentally delayed groups and from typically developing children. 16 -19 Specifically, children with autism have marked difficulty disengaging attention from an ongoing central stimulus to orient toward a newly appearing peripheral stimulus; they get stuck on the central stimulus. This task was administered at baseline and both follow-up assessments.
Parent Questionnaires
A Gastrointestinal Symptoms Questionnaire was designed for this study. At baseline, parents answered 12 yes/no questions about their child's eating habits and GI symptoms and indicated the frequency and/or severity of existing problems in their child with autism and a nonaffected sibling.
A Treatment Behavior/Side Effect Rating Scale was also developed for the current study. This parent-rated questionnaire includes behavioral (eg, irritable) as well as physiologic items (eg, rashes, diarrhea), rated on a 4-point scale ranging in frequency/ severity from not at all to very much.
The Autism Behavior Checklist (ABC) 20 was also used. This 57-item checklist of autistic behaviors is comprised of 5 subscales (Sensory, Relating, Body and Object Use, Language, and Social and Self-Help) and has good interrater reliability (0.87). Parents completed the latter 2 scales at the end of each week.
Statistical Analysis
Separate repeated-measures analyses of variance (ANOVAs) were conducted to examine group (secretin; secretin vs placebo; placebo) differences on the variables of interest (ADOS-G, IQ, language scores, and number of failures to disengage attention). Separate 2 (treatment groups) ϫ 5 (baseline, as well as 1 and 2 weeks after each injection) ANOVAs were also conducted on ABC subscale scores. Independent samples t tests were used to further explore group differences on ABC subscale scores at each of 10 weeks after baseline. To correct for multiple t tests, the significance level was adjusted as follows: P ϭ .05/10 ϭ .005. The data were then analyzed by subgroups (presence/absence of GI symptomatology, cognitive level, and history of regression) using 2 (treatment groups) ϫ 2 (level of subgroup) ϫ 2 (post 1, post 2) repeatedmeasures ANOVAs to test for treatment differences in language and autistic symptoms; IQ differences were also examined across GI and regression subgroups.
RESULTS
Four children did not complete the study (2 girls and 2 boys; 2 secretin and 2 placebo). One discontinued for personal reasons after the second injection (secretin), 1 withdrew because of increased hyperactivity after the first injection (placebo), 1 family lost contact after the first injection (placebo), and 1 (secretin) was excluded after the final assessment be-cause another medication was introduced during the course of the study. Thus, data were analyzed for 64 children (9 girls and 55 boys) with a mean age of 62.73 months (range: 35-92 months). Based on previous claims of considerable improvements in language, 4 we anticipated an overall moderate effect size on the PLS-3. Therefore, a sample size of 64 was calculated to be sufficient to obtain power of 0.8, with ␣ set at 0.05. 21 Twenty-eight children were between the ages of 2 years 11 months and 4 years 11 months, and 36 children were between the ages of 5 years 0 months and 7 years 8 months. Eight children were enrolled while on medication (having begun at least 6 weeks before the baseline assessment): 2 were on selective serotonin reuptake inhibitors (1 secretin and 1 placebo), 2 on anticonvulsant medication (1 secretin and 1 placebo), 2 on stimulants (1 secretin, dextroamphetamine and 1 placebo, methylphenidate), 1 on melatonin (placebo), and 1 child was on ranitidine (placebo).
Participant characteristics for each group at baseline are reported in Table 1 . Independent samples t tests yielded no significant baseline differences between treatment groups on Leiter-R Brief IQ 12, 13 scores (t ϭ Ϫ0.72), Receptive (t ϭ Ϫ0.3), Expressive (t ϭ Ϫ0.49), or Total (t ϭ 0.13) Language scores, or on autistic symptomatology, as measured by the ADOS-G (t ϭ Ϫ0.42; all P values Ͼ.05). Based on GI questionnaire data, 3 children were reported to have reflux (1 secretin and 2 placebo) and 15 children (23%) had diarrhea, defined as 3 or more stools a day (7 secretin and 8 placebo). The incidence of diarrhea is consistent with (if not somewhat lower than) the rate reported in a larger sample of autistic children (39%) based on a questionnaire study that was conducted with a larger sample of our clinic population and will be reported separately (T. Kagan-Kushnir and W. Roberts, unpublished data). Thus, we were confident that our sample was not biased in favor of a GI-affected group.
The total sample was divided into low (standard score Ͻ70) and high IQ (standard score Ͼ70) based on Leiter Brief IQ (n ϭ 53) or Vineland (n ϭ 11): 23 children (10 secretin and 13 placebo) fell into the low IQ category, and 41 (22 secretin and 19 placebo) fell into the high IQ group. According to ADI-R criteria, 27 children (12 secretin and 15 placebo) experienced an historical pattern of regression characterized by a period of language development that included the regular and flexible use of at least 5 words (excluding mama and dada), which were subsequently lost.
ANOVAs failed to yield any significant main effects or interactions on measures of autistic symptomatology (ADOS-G, ABC) Scores on the Relating subscale of the ABC differed significantly between groups 1 week after the first injection, with the placebo group (m ϭ 21.08) showing less severe autistic symptomatology than the secretin group (m ϭ 27.91; t ϭ Ϫ3.14; P Ͻ .005).
Subgroup Analyses
Subgroupings based on presence or absence of GI symptomatology, IQ, or history of regression failed to yield significant treatment differences between subgroups on any of the measures used (all P values Ͼ.05). Data from the Side-Effects Rating Scale also failed to show any systematic relationship between secretin and improved bowel functioning, although our study was not designed specifically for this purpose.
Anecdotal Parental Reports
Although still blind to group membership, parents anecdotally reported the following changes: sleep improvement in 7 children (4 secretin and 3 placebo), 4 of whom had diarrhea according to the GI questionnaire (3 secretin and 1 placebo); toilet training in 2 children shortly after injection (both secretin, 1 with reported diarrhea); night-time toileting in 3 children (2 secretin and 1 placebo); increased eye contact in 6 children (4 secretin and 2 placebo); and more connectedness in 5 children (4 secretin and 1 placebo).
Of these, only 3 children (all secretin; the first of whom had diarrhea according to the GI questionnaire) reportedly improved across several domains. The parents of one 4-year-old boy reported achievement in toilet training, solidification of stools, and improved sleep, as well as improved eye contact, socialization, and speech. Parents of another 4-yearold boy reported improved speech, awareness, and connectedness, but more aggression at school. In this child, improvement on the ADOS-G was noted initially but gains were not maintained. Parents of a 3 1 ⁄2-year-old boy reported improved articulation, full sentences for the first time, and increased sociability, including friendliness, a sense of humor, and eye contact, as well as hyperactivity. In all 3 children, however, there was no evidence of gains on formal clinical or psychological measures; the improvement documented on language measures did not exceed the range seen in either treatment group.
Adverse Events
The following adverse events were reported only in the secretin group and may reflect a drug effect.
• One child had a rash 1 week after the first infusion.
• One child had fever and tachycardia with vomiting within a few minutes after each injection.
• One child demonstrated possible photosensitivity.
• Three children had an increase in irritability (eg, crying, negativity, temper tantrums) starting 1 day after each injection and lasting up to 2 weeks.
• Twenty-one percent of secretin injections resulted in a generalized flushing reaction of the neck, face, and/or chest immediately after the infusion.
The following adverse events were found in both the secretin and placebo groups.
• The 3 (secretin) children with irritability also had concurrent hyperactivity (restlessness, constant movement). Two children from the placebo group were also reported to have an increase in hyperactivity. One additional child from the placebo group was reported to become so hyperactive that parents withdrew from the study, not wanting the second injection.
• Three children showed an increase in aggression (2 secretin and 1 placebo).
DISCUSSION
This study examined the effect of 2 infusions of porcine secretin on autistic symptoms and on cognitive and language measures in children with autism. Consistent with the findings from single-dose studies, 5,7 double doses of secretin failed to yield significant differences between groups (secretin vs placebo) on any of the measures used. Receptive and expressive language improved in both groups, but amount of improvement did not distinguish between groups, suggesting that these gains were likely attributable to factors, such as familiarity with the testing situation, maturation, and/or ongoing behavioral interventions. We further explored our null findings by subdividing groups by GI symptomatology, cognitive level, and history of regression (any of which might reflect different underlying pathologies) and continued to find no evidence for the effectiveness of secretin.
Close scrutiny of the data from those cases for whom parents reported marked improvement failed to show any sustained clinical improvement. Furthermore, these children did not seem to share any common characteristic, such as diarrhea, which might have related to improved behavior.
The finding that language skills improved in both groups serves to underscore that at least some of our measures are sensitive to relatively subtle and shortterm changes in behavior. Although we cannot completely rule out the possibility that practice effects contributed to our observed gains in language performance (in both groups), language tests (such as the PLS-3), which measure children's attainment of language, are less susceptible to such effects than other types of measures, such as performance tasks. 22 We also emphasize that improvements in language have been a focus of parental reports on the effects of secretin. 4 Our data on language corroborate parents' observations, although the failure to show that such improvements are secretin-related underscores the importance of double-blind, placebo-controlled studies.
Despite our failure to show any secretin effects in a subgroup with GI symptoms, we cannot preclude the possibility that subgroupings based on some GI measure other than diarrhea (eg, reflux or chronic inflammation) might yield more homogeneous groups. Also note that there might be considerable heterogeneity in autistic children with bowel problems; in some there may be underlying GI pathology, whereas in others the problem may be related to factors, such as diet and/or anxiety. We do emphasize in this context that a large proportion of our sample was reported to have bowel, sleeping, and/or eating problems, and that these symptoms seemed to fluctuate considerably in both groups (secretin and placebo). Relief from such symptoms might be associated with enhanced capacity to function (eg, greater compliance, more consistent skill performance, and/or a better state for learning) and might contribute to the improvements reported by parents.
Although hopes had been raised for a pharmaceutical solution for children with autism, we found no evidence for the efficacy of secretin. The present study extends previous research by failing to show any positive effects for 2 doses of porcine secretin in either a large sample or in subgroups based on GI functioning, cognitive level, or history of regression.
